

Loxo Oncology, Inc.
Form 15-12B
February 25, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION
OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-36562

LOXO ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Lilly Corporate Center
Indianapolis, Indiana 46285
Telephone: (317) 276-2000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.0001 par value per share

(Title of each class of securities covered by this Form)

None

(Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6
Rule 15d-22(b)

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Loxo Oncology, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Loxo Oncology, Inc.

Date: February 25, 2019

By: /s/ Darren J. Carroll
Name: Darren J. Carroll
Title: President